Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align

 
• By Cathy Kelly

Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.

Drugs Need More Data On Safety, Effectiveness, Medicare Says • Source: Alamy

More from Medicare

More from Government Payers